Background Charcot-Marie-Tooth disease is a common inherited neuropathy where patients may be sensitive to adverse effects of certain medicines; however, information about medication safety in this group of people is limited. Objective This study aimed to investigate the experience of Australian individuals with Charcot-Marie-Tooth disease in using medications, including perceived impact of drug-induced adverse effects. Secondarily, it aimed to determine whether individuals with Charcot-Marie-Tooth disease feel adequately supported to make decisions about medication safety. Setting Focus groups and interviews (face-to-face or telephone) of individuals with Charcot-Marie-Tooth disease in Australia. Method A mixed methods qualitative study was conducted between September 2015 and August 2016 using semi-structured interviews. Thematic analysis of interview transcripts was conducted independently by two researchers using inductive coding until concept saturation was achieved. Main outcome measure Perceptions of medicines safety in people with Charcot-Marie-Tooth disease, including barriers to making informed decisions about medication safety. Results Twenty-four adults with Charcot-Marie-Tooth disease participated. Anaesthetics (18%) and pregabalin (15%) were the medications most frequently reported as impacting on Charcot-Marie-Tooth symptoms. Participants sought medication information primarily from general practitioners or neurologists. The main barriers identified by participants were a perceived poor understanding in non-specialist health professionals about Charcot-Marie-Tooth disease and lack of attention to medication safety concerns in people with Charcot-Marie-Tooth disease; this resulted in dissatisfaction about the advice provided. Many individuals who faced uncertainty in obtaining and understanding medicines information turned to internet resources, peer groups, and use of complementary and alternative medicines to self-manage Charcot-Marie-Tooth exacerbations. Conclusion Participants reported drug-related adverse effects and a difficulty in obtaining safety information about medication. This study highlights the need for improved evidence about medication safety in people with Charcot-Marie-Tooth disease. Development of evidence-based resources, increased awareness amongst health professionals about Charcot-Marie-Tooth disease and a team-based care approach could facilitate shared decisions about medication use for people with Charcot-Marie-Tooth disease.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Szigeti K, Lupski JR. Charcot-Marie-Tooth disease. Eur J Hum Genet. 2009;17(6):703–10.
Lencioni T, Piscosquito G, Rabuffetti M, Bovi G, Calabrese D, Aiello A, et al. The influence of somatosensory and muscular deficits on postural stabilization: insights from an instrumented analysis of subjects affected by different types of Charcot-Marie-Tooth disease. Neuromuscul Disord. 2015;25(8):640–5.
Bamford NS, White KK, Robinett SA, Otto RK, Gospe SM. Neuromuscular hip dyplasia in Charcot-Marie-Tooth disease type 1A. Dev Med Child Neurol. 2009;51:408–11.
Padua L, Aprile I, Cavallaro T, Commodari I, Pareyson D, Quattrone A, et al. Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study. Neurol Sci. 2008;29(3):157–62.
Barreto LC, Oliveira FS, Nunes PS, de França Costa IM, Garcez CA, Goes GM, et al. Epidemiologic study of Charcot-Marie-Tooth Disease: a systematic review. Neuroepidemiology. 2016;46:157–65.
Denton S, Schofield D, Poynten J, Stanley A (2015) Reducing the health burden of Charcot-Marie-Tooth in Australia. https://cmtaustralia.org.au/wp-content/uploads/2020/04/reducing-health-burden-of-CMT-Aust.pdf Accessed 14 July 2020.
Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 2016;6:e010035. https://doi.org/10.1136/bmjopen-2015-010035.
Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci. 2006;242:47–54.
Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2003;3(1):86–92.
Ibañez-Juliá MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, et al. Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncol. 2018;57(3):403–11.
Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441–57.
Isbister GK, Burns J, Prior F, Ouvrier RA. Safety of nitrous oxide administration in patients with Charcot-Marie-Tooth disease. J Neurol Sci. 2008;268(1–2):160–2.
Carlsen B, Glenton C. What about N? A methodological study of sample-size reporting in focus group studies. BMC Med Res Methodol. 2011;11(26):2–10.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
Vinci P, Lapi G. Anaesthetic management in Charcot-Marie-Tooth disease type 2 due to a mutation in the mitofusin-2-gene. J Anaesthesiol Clin Pharmacol. 2011;27(2):286–7.
Ohshita N, Oka S, Tsuji K, Yoshida H, Morita S, Momota Y, et al. Anesthetic management of a patient with Charcot-Marie-Tooth disease. Anesth Prog. 2016;63(2):80–3.
Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67(9):1265–89.
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2019, Issue 1. Art. No.: CD007076.
Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. Med J Aust. 2013;199(9):624–5.
CMTA. Neurotoxic Medications. https://www.cmtausa.org/living-with-cmt/managing-cmt/medications/. Accessed 14 July 2020.
Längst G, Seidling HM, Stützle M, Ose D, Baudendistel I, Szecsenyi J, et al. Factors associated with medication information in diabetes care: differences in perceptions between patients and health care professionals. Patient Prefer Adherence. 2015;9:1431–41.
Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient-physician interaction. Health Policy. 2012;105:154–64.
Crowe AL, McKnight AJ, McAneney H. Communication needs for individuals with rare diseases within and around the healthcare system of Northern Ireland. Front Public Health. 2019;7:236. https://doi.org/10.3389/fpubh.2019.00236.
Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reations on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148–52.
Babac A, von Friedrichs V, Litzkendorf S, Zeidler J, Damm K, von der Schulenburg JMG. Integrating patient perspectives in medical decision-making: a qualitative interview study examining potentials within the rare disease information process in practice. BMC Med Inform Decis Mak. 2019;19:188. https://doi.org/10.1186/s12911-019-0911-z.
Maghsoodi N, Crook MA. A case of Charcot-Marie-Tooth (CMT) disease with hypercholesterolaemia and statin side-effects: a case report and literature review. J Clin Neurosci. 2017;38:57–9.
Gibson Smith K, Booth JL, Stewart D, Pfleger S, McIver L, MacLure K. Supporting shared decision-making and people’s understanding of medicines: an exploration of the acceptability and comprehensibility of patient information. Pharm Pract. 2017;15(4):1082.
Newman TV, San-Juan-Rodriguez A, Parekh NM, Swart ECS, Klein-Fedyshin M, Shrank WH, et al. Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization and economic outcomes: an umbrella review. Res Soc Adm Pharm. 2020. https://doi.org/10.1016/j.sapharm.2019.12.016.
Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial. BMJ Open. 2013;3:e002361. https://doi.org/10.1136/bmjopen-2012-002361.
Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, et al. The impact of patient-centered care on outcomes. J Fam Pract. 2000;49(9):796–804.
The authors would like to thank the Charcot-Marie-Tooth Association of Australia who have supported our project as well as all participants for their valuable insights into this topic. We thank Rebecca Pratchett for her advice on using NVivo and Lyn Todd for her editorial oversight.
This project was funded by the Charcot-Marie-Tooth Association of Australia.
Conflicts of interest
All authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Socha Hernandez, A.V., Deeks, L.S. & Shield, A.J. Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective. Int J Clin Pharm (2020). https://doi.org/10.1007/s11096-020-01123-z
- Charcot-Marie-Tooth disease
- Drug-induced neuropathy
- Medication information
- Medication safety
- Patient perspective
- Qualitative analysis